45 results about "Alkyl nitrile" patented technology

Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1 and W, R1 is (CH2)n—CH(OR2)—(CH2)mE1, —(CH)═C(OR2)—(CH2)mE, —(CH2)n—CH(Y)—(CH2)mE or (CH)═C(Y)—(CH2)mE; wherein E is COOR3, C1–C3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1–C6 alkyl, haloalkyl and aryl-C0-4-alkyl; R2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR4, —COOR4, —CONR5R6, —C(S)R4, —C(S)OR4 or C(S)NR5R6, R3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH2—, —CH2CH2— or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R1. R4–R6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2

A method of preparing a pigment includes the steps of: a) providing a mixture including:a pigment selected from the group of pigments including at least 50 wt % of C.I. Pigment Violet 23, C.I. Pigment Red 146, C.I. Pigment Red 176, C.I. Pigment Red 177, C.I. Pigment Violet 19 and C.I. Pigment Orange 13 based on the total weight of the pigment;alkyl nitrile; andat least one acid selected from the group consisting of sulfuric acid and chlorosulfuric acid, with the acid present in the mixture in amount of more than 2 wt % based on the total weight of the pigment;b) heating the mixture for more than 2 hours to a temperature of at least 70° C.; andc) filtering the mixture and washing the filtrand with a washing liquid containing water until the filtrate has a pH between 4 and 7. Pigments obtainable by the method and non aqueous pigment dispersions are also disclosed.

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ω-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ω-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The invention discloses an aripiprazole drug co-crystal and a preparation method thereof. Using aripiprazole as an active pharmaceutical ingredient and resveratrol as a precursor, the aripiprazole and white Veratrol co-crystals. The preparation method is as follows: equimolar aripiprazole and resveratrol are put into a mortar for grinding, ketone or alkyl nitrile solvent is added before grinding, manually ground for 30 minutes, and vacuum-dried at 40-60 DEG C to obtain aripiprazole. azole drug co-crystals. The powder dissolution experiment of aripiprazole and resveratrol showed that the dissolution rate of aripiprazole slowed down in both the acetate buffer solution of pH=4.0 and the phosphate buffer solution of pH=6.8, showing a potential sustained release effect. Therefore, by preparing the aripiprazole co-crystal into an intramuscular injection, it may be possible to achieve a long-term treatment of schizophrenia and reduce the effect of muscle stimulation.

The invention relates to a flame retardant anti-bacterial composite modifier used in the fiber field and a preparation method thereof. The active components of the flame retardant anti-bacterial modifier are alkyl phosphate and alkyl guanidine; and the preparation method of the flame retardant anti-bacterial composite modifier comprises the following steps of: (1) preparing alkyl tetrol phosphoric acid ester; and (2) taking alkyl tetrol phosphate ester B, alkyl guanidine C and p-benzoic acid alkyl nitrile D which have the equal amount of substance, adding concentrated sulfuric acid and dicyclohexylcarbodiimide / N, N'-diisopropyl carbodiimide (DCC / DIC) as catalysts, wherein the mass ratio of the concentrated sulfuric acid to the alkyl tetrol phosphate ester B is 1:2-4, the mass ratio of DCC / DIC to the alkyl guanidine C is 1:2-5, rising the temperature to 70 to 200 DEG C, after reacting for 3-10h, cooling, filtering and drying to obtain the solid composite modifier E. The flame retardant anti-bacterial composite modifier has the advantages of having the flame retardant anti-bacterial performance, good thermal stability, being capable of meeting the high temperature processing requirement and being not easy to degrade; and products machined and prepared by using the composite modifier are not easy to oxidize and change color; and the flame retardant anti-bacterial composite modifier is widely applied.

The invention discloses a preparation method of gamma-carboxylated alkyl nitrile compounds. The method uses an olefin compound of formula II, a carboxylic acid compound of formula III, and an alkyl nitrile compound of formula IV in a nickel catalyst, silver A series of γ-carboxylated alkyl nitrile compounds with various structures were prepared by carrying out the difunctionalization reaction of olefins under the condition of oxidizing agent. The synthesis route of the gamma-carboxylated alkyl nitrile compound of the present invention has the advantages of easy source of raw materials, low price of the catalytic system, wide application range of reaction substrates and high yield of target products.

Compounds of Formula (I) wherein R<1>, A, R<2>, R<3>, R<4>, R<5>, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.